Background: Currently there is no standard adjuvant treatment following surgical resection of metastatic melanoma. We investigated whether surgery followed by autologous tumor cell-BCG vaccination was beneficial for malignant melanoma patients. In this study we focus on the prognostic value of DTH response following vaccination therapy.
Introduction
Malignant melanoma shows a world-wide increase in incidence of 5% per year. At the moment only radical surgery in early stages of disease can be curative. When the thickness of the melanoma is <1.5 mm (stage I melanoma according to the American Joint Committee on Cancer [AJCC]) five-year survival is > 90%. In stage II disease (melanoma thickness ^ 1.5 mm) this survival rate is 75%, and in case of lymph node metastases (stage III), it is 10%-50% depending on the number of nodes involved. After haematogenous spread of the disease (stage IV) median survival is as low as four to eight months and five-year survival rate is less than 5% [1] .
Recently, high-dose interferon-a (IFN-a) has been registered in the US and several European countries for adjuvant treatment after surgery of stage lib and III melanoma. This was based on the results of a relatively small trial showing a slight improvement in recurrencefree and overall survival, but with high toxicity [2] . In a recent analysis of a much larger trial by the same investigators it was demonstrated that treatment with IFN-a resulted in improved recurrence-free survival, but failed to affect overall survival of high-risk melanoma patients [3] . Chemotherapy has a limited activity in melanoma. Cytotoxic drugs with a proven effect in the adjuvant setting are currently not available. Dacarbazine, the most frequently used palliative cytotoxic drug in stage IV disease shows a response rate of only 15%-20% and the duration of remissions is generally short [4] .
The observed biological behavior of malignant melanoma suggests that this malignancy is more immunogenic than other types of cancer. In fact, occasionally spontaneous complete remissions occur and in 3% to 15% of all melanomas only metastases are found and no primary tumor, most likely the result of spontaneous resolving of the primary lesion, although in rare cases the alleged metastasis will be a non-cutaneous primary melanoma [1, 5] . Moreover, humoral and cellular immune reactivity towards melanoma cell antigens have been reported on several occasions and lymphocytic infiltration was associated with regression of melanoma metastases [6] . Non-specific immunotherapy with IL-2 and/or IFN-a showed response rates comparable to chemotherapy, but was accompanied by relatively high toxicity and is now under investigation in combination with chemotherapy. The first reports about this combination regimen showed markedly increased response rates. However, toxicity was significant, while no impact on survival was observed [7] [8] [9] .
Active specific immunotherapy (ASI) is a technique which aims at enhancing a specific immune response against malignant cells. Various vaccine types have been investigated, such as allogeneic melanoma cell lysates [10] , allogeneic whole cell mixes [11] , autologous whole cells [12] , combinations of synthetic melanoma antigens [13] , genetically modified autologous whole melanoma cells [14] and synthetic-peptide pulsed autologous dendritic cells [15] .
The potential advantage of employing autologous whole cell vaccines is that such vaccines most likely contain all tumor antigens present on the cell surfaces of the individual patient's tumor and have a perfect HLA match. This might be of particular importance since it is still unknown which antigens are most relevant for the development of protective anti-tumor immunity.
Recently, we demonstrated that ASI induced a significant reduction of tumor recurrence in stage II colon carcinoma patients in a multicenter randomized trial [16] . In the present study, we again used an autologous whole cell vaccine and bacillus Calmette-Guerin (BCG) as an immune stimulatory adjuvant for AJCC stage III and stage IV melanoma patients. Whenever possible, all clinically evident metastases were resected before vaccination, as there is evidence that immunotherapy may be most effective in a minimal residual disease setting [17] . In this report we focus on the delayed type hypersensitivity reaction (DTH) to autologous vaccines as an early predictor of clinical outcome.
Patients and methods

Patients
Patients with at least one surgically resectable melanoma metastasis were selected for this study. Whenever possible, radical metastasectomy was performed. After confirmation of the diagnosis was done, all tumor tissue obtained during this procedure was used for vaccine preparation. A WHO performance status of 0 or 1 was required. Patients were only eligible when sufficient tumor cells were available for the production of a minimum of three vaccines, indicating that the metastases needed to have a volume of at least 1 cm 3 . The use of immune suppressive drugs was a reason for exclusion from this trial as was the participation in any other study. Patients that had previously been subjected to systemic anti-melanoma therapy were only eligible when showing progressive disease. The absence of macroscopic residual disease was assessed by pathology, a total physical examination and radiological examination of the abdomen and chest. All patients signed informed consent forms prior to immunization.
Vaccine preparation
Nine Dutch hospitals participated in this study. Surgery was performed in the referring hospital. Immediately after surgery the part of the tumor tissue not required for pathological examination was excised and transferred to the vaccine production laboratory-of the UniversityHospital Vrije Universiteit, Amsterdam. The tumor was dissociated as previously described [17] [18] [19] . Briefly, tumor tissue was minced into small pieces and then incubated with a collagenase and DNAse solution. Single cells were then harvested through a 100 um gauze. After this procedure a sample for bacteriology control was taken and viability was tested using trypan blue exclusion. Cells were then aliquotted (15-20 x 10 6 viable cells per vial) and cryopreserved using a linear freezer. Vials were stored in liquid nitrogen until vaccination. For each patient an attempt was made to produce as many vaccines as possible with a minimum number of three.
Vaccination procedure
Vaccination started four to five weeks after surgery to minimize the possible immune suppressive influence of surgery and anesthesia. If post-surgical radiotherapy was given, the vaccination procedure was postponed until four weeks after this treatment.
On the day of vaccination, after thawing, cells were counted and viability was assessed. The cells were irradiated (200 Gy) and to the first two vaccines 10 7 viable fresh-frozen BCG organisms were added. Patients with a medical history of tuberculosis received half the dosage of BCG. The final volume of the vaccines was 0.2-0.3 ml.
Vaccines were administered intra-cutaneously near sites of regional lymph nodes, excluding sites were regional lymph node dissection had been performed. Generally the first two vaccines, containing BCG were injected on the right and left anterior thigh respectively at an interval of one week. In the following week the third vaccine was given in one of the upper arms. Further vaccinations were given in alternating arms at different intervals, depending on the DTH response to the preceding vaccination. Response to the vaccines not containing BCG was measured by the size of induration and erythema 48 hours after injection. This was always done by the same investigator (HEG). Induration was assessed by the pen method [20] , For measurement of induration a line was drawn with a pen from 1-2 cm away from the margin of the skin test reaction towards the lesion. The pen is held at a 45° angle and moderate pressure is applied. The pen is advanced until resistance is met. indicating the edge of the area of induration. This procedure is performed in four directions.
In general, if induration was less then 10 mm, the next vaccine was given within one to four weeks. If induration was more then 10 mm the interval was two to six months. When tumor recurrence or progression was observed vaccinations were stopped.
Statistical analysis
Cox' proportional hazards model and the log-rank test for linear trend were used to determine the relationship between DTH and survival. Survival curves were estimated by the non-parametric Kaplan-Meier method. The log-rank test was used for determining differences between survival curves. Student's /-test was used for analyzing differences between the maximum induration in patients with and without evidence of residual disease at start of vaccination treatment. Calculations were made with SPSS 9.0 for Windows software.
Results
Patients
Between 1987 and 1998, tumors of 139 patients were processed for vaccine preparation. For 102 of these 139 patients adequate vaccines could be produced. Following surgical resection of metastases, 81 patients could be immunized with autologous melanoma tumor cells. Reasons for not receiving vaccination therapy were lack of sufficient tumor cells (n = 35), refusal of the patient to participate in this clinical trial after prior approval (n = 16), and very rapid disease progression between surgery and the planned date of the first vaccination (// = 7). In October 1999 data were collected for followup of all vaccinated patients. The median follow-up time for all patients was 17.1 months. For patients still alive median follow-up was 37.6 months. Patient characteristics are shown in Table 1 . Patients were divided into four subgroups depending on stage (AJCC stage III or IV) and on evidence of residual disease after metastasectomy. During surgery three patients with regional node metastases appeared to have nodal tumor growth into inoperable structures (brachial plexus x 2, femoral artery). These patients were classified as III ED.
The median number of vaccinations was four, ranging from two to sixteen. In nineteen patients start of vaccination was postponed because of radiotherapy. Preceding ASI, eight patients had been given systemic therapy (IL-2, IFN-oc, DTIC). For these patients the time between the last systemic treatment and surgery was 3.2 months (range 2.3-7.1). Two patients received an adjusted dosage of BCG because of a medical history of tuberculosis.
Vaccine quality
The average weight of tumor received from the patients that could be vaccinated was 5.3 (range 0.9-19.4) g. The average yield of tumor cells per gram of tissue was 37 (range 1.1-281) x 10 6 . The average viability of the tumor cells after thawing was 86% (range 66-100). A tumor weight of two grams was normally sufficient for producing three vaccines. All tumors were sterile.
Side effects
Fifty-three patients (65%) developed some degree of ulceration after the first two injections, containing BCG, most of which healed within three months. The immunizations without BCG did not cause ulceration. A few patients developed painful swollen lymph nodes near the sites of vaccine injection. Systemic reactions such as fever and chills were occasionally seen after the BCG-containing injections. No serious adverse effects were observed and admission to the hospital was never necessary.
Survival
There was a statistically significant difference in survival between stage III and stage IV patients (P < 0.0001). In stage III patients as well as in stage IV patients ED was associated with decreased survival compared to NED (P < 0.0001 and/ 3 = 0.0016). Survival for stage III NED and stage IV NED patients did not differ statistically significant (P = 0.076) as was the case for stage III ED and stage IV ED (P = 0.46).
After radical surgery for regional nodes, a five-year survival rate of 48% was observed. For these patients -7) 1 (1-4)
3(1-10+)
Abbreviations: ED -evidence of disease at start ASI; NED -no evidence of disease at start ASI. a Sites of visceral metastases: NED-lung 2 x, duodenum 1 x; ED: lung 6 x, mediastinum 1 x, CNS 3 x, bone 2 x, generalized 3 x. median overall survival was 38.1 months. Stage IV patients who had undergone radical metastasectomy showed a five-year survival rate of 34% and a median survival of 15.8 months.
Patients with evidence of residua! disease had a median survival of less than one year. Events and survival data are summarized in Table 2 . Figure 1 shows overall survival curves for all patients. Figure 2 shows disease-free/progression free survival for all patients. Table 3 . Maximum DTH responses. 
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DTH assessment
All patients developed some degree of induration and erythema at the site of the first two vaccinations, containing BCG. Of all the patients, 93% had a maximum induration of more than 5 mm and 80% had a maximum induration of more than 10 mm after vaccinations not containing BCG. The maximum DTH response was defined as the size of the largest skin reaction after any of the consecutive vaccinations in a patient. The median maximum induration was 14 mm and was reached on average after 3.9 vaccinations. Median maximum induration of patients with known residual disease was 10 mm, while the patients with no evidence of disease had median maximum indurations of 16 mm (P = 0.013) (Table 3 ). There was a clear relationship between size of DTH response and clinical outcome. In Figure 3 patients are divided in groups depending on size of maximum induration. Arbitrarily groups of 10 mm were used for maximum diameter of induration. Figure 3 shows that improved survival was observed with increasing maximum induration size (P < 0.0001). Induration after the third vaccination also correlated with survival (/> = 0.047).
Within each of the four separate patient groups no significance was reached for the correlation between maximum induration and survival (III NED: P = 0.071, III ED: P = 0.49, IV NED: P = 0.53, IV ED: P = 0.43). Combining the data of both NED groups showed a significant correlation for induration and survival (P = 0.026).
Median maximum erythema was 42.6 mm after an average of four vaccinations. Again, a significant correlation between maximum size of erythema and overall survival was observed (P = 0.004). The size of erythema after the third vaccination did not correspond significantly with survival (P = 0.20).
In Table 4 we summarised the data of median size of induration after each consecutive vaccination in stage III NED patients that have been free of tumor recurrence until end of follow-up, showing that induration fails to increase.
Discussion
In this study an evaluation is presented of 81 patients treated for metastatic melanoma by means of aggressive surgery, followed by autologous tumor cell vaccination using BCG as an immune stimulatory adjuvant. To our knowledge, this is the largest series of metastatic melanoma patients treated according to this strategy ever published. In this study we show a clear relationship between the size of DTH reaction and clinical outcome (Figure 3 ). For both maximum erythema and maximum induration the correlation with survival was significant.
Previous studies have already suggested that strong DTH responses during vaccination therapy in melanoma patients is of strong prognostic value [21] . Harris et al. showed a correlation between DTH response and both disease-free and overall survival in colon cancer patients given adjuvant vaccination with an autologous vaccine [22] . Figure 3 The relationship between maximum size of induration after vaccination and cumulative overall survival. Patients with large indurations have a better prognosis than patients with small indurations after vaccination (P < 0 0001).
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The observation that DTH-responses and survival correlate significantly could indicate that patients with strong DTH-reactions develop strong anti-tumor immunity after vaccination. However, our data show that the ability of patients to respond to immunization is dramatically decreased for patients with residual tumor at start of vaccination. This lack of response is likely the result of the secretion of immune suppressive factors such as IL-10, TGF-(3, VEGF or an acquired defective T-cell/dendritic cell function [23] . Additionally, no significant relationship could be observed within each of the four separate patient groups, possibly because of small numbers. Therefore, it cannot be ruled out that the strong correlation observed between size of induration and survival is merely a reflection of the patients general immune status.
In this study ASI seems to be effective in melanoma patients with a minimal residual disease setting, following metastasectomy. With this approach a five-year survival rate of almost 50% in stage III melanoma patients and more than 30% in stage IV disease was observed what is higher than with surgery alone [1] .
Bcrd et al. suggested that tumor-induced suppressor T cells might play an important role in the lack of response of the immune system of cancer patients. They demonstrated, in melanoma patients with clinical evidence of metastases, that the administration of cyclophosphamide, three days prior to vaccination with autologous tumor cells, was able to break the immunologic tolerance and significantly increase the DTH response against these tumor cells [12, 24] . This cyclophosphamide-induced immune potentiation might be an explanation for the relatively high response rate (4 CR, 1 PR) observed in their 40 vaccinated patients. In the study presented here no clinical responses were observed in the patients with evidence of disease, most likely due to tumor induced immune suppression, as suggested by the low DTH responses. Our data suggest that ASI is not effective in patients with residual disease when no additional treatment is given. The combined administration of chemotherapy, which reduces tumor load and may overcome immune tolerance, and cytokines, which may restore and enhance immunological competence, could be an important tool in the development of new vaccination therapies. In accordance with this theory, Leong et al. not only gave systemic cyclophosphamide prior to vaccination but also administered rhGM-CSF locally at the site of induration in the five-day period following vaccination, by giving daily injections. This strategy resulted in an objective response rate of 20% in stage IV melanoma patients, including 2 complete remissions [25] .
The number of vaccinations that should ideally be given has yet to be clarified. Different groups have administered different numbers of injections. Morton, using an allogeneic tumor cell vaccine, continues giving vaccinations for many years [11, 26] . In a vaccination study for colon carcinoma patients, performed at our institution, it was shown that giving a booster injection after six months resulted in a stronger DTH response and an improved disease-free survival compared to studies not using this booster injection [16] . Theoretically, the possibility exists that the continuation of the administration of antigens, without giving immune stimulatory adjuvants, could induce immunologic tolerance [27] . We evaluated the data of this trial to investigate whether the number of vaccinations was important for the development of anti-tumor immunity. We hypothesized that if continuing giving vaccinations would be better, the size of the induration after each vaccination should increase [28] . For this reason we collected the data of the stage III patients without evidence of residual disease at start of ASI treatment and no sign of tumor recurrence after vaccination therapy (n = 15). In these patients the effect of tumor-induced immune suppression on DTH responses is unlikely. As is shown in Table 4 , the average size of induration failed to increase after consecutive vaccinations, suggesting that the effectiveness of extra vaccinations administered without immune stimulatory adjuvants is limited.
In conclusion, our results show that large-scale preparation of autologous melanoma cell vaccines is feasible, while vaccination results in the development of DTH responses that correlate strongly with survival. Radical surgery, followed by ASI seems to be beneficial in stage III and stage IV melanoma patients, warranting further investigations for this non-toxic treatment modality.
